For Cancers

Introduction to Cancers

Cancer is a major public health issue of global concern and the most devastating of the non-communicable diseases. According to Global Cancer Statistics 2018, there were more than 18 million new cancer cases and 9.6 million deaths caused by cancer in 2018. Cancer cases are expected to reach 29.5 million with a death of 16.4 million annually by 2040 worldwide. Humans suffer from about 200 different types of cancer. Among them, lung, colorectal, stomach and liver cancers had the highest mortality rates (18.4%, 9.2%, 8.2% and 8.2% respectively)^[1]. Traditional cancer treatments, such as radiotherapy and chemotherapy, have significantly improved cancer survival rates. However, these methods are often accompanied by serious adverse effects such as systemic toxicity and multiple drug resistance. The development of oligonucleotide therapeutics offers great potential for the treatment of cancer.

Oligonucleotide Therapeutics for Cancers

Oligonucleotide therapeutics for the treatment of cancer have been studied for decades with favorable in vitro results. However, there are currently no approved oligonucleotide therapeutics for cancer yet. Most oligonucleotide therapeutics for cancer are still in clinical phase 1 or 2. As of January 2021, a total of 229 clinical trials have been registered on ClinicalTrials.gov for 60 oncology oligonucleotide therapeutics. Of these, 195 are using antisense oligonucleotides (ASOs) as an intervention, 17 trials for small interfering RNAs (siRNAs), seven trials for microRNAs (miRNAs), nine trials for aptamers, and one trial for DNAzymes (Figure 1a). There are currently 15 oligonucleotide therapeutics in phase 2/3 or phase 3 trials (all for ASOs) (Figure 1b)^[2].

Figure 1. Summary of clinical trials for oligonucleotide therapeutics in oncology. (a) Numbers of trials for different types of oligonucleotide therapeutics; (b) Trials status.

We are Developing Products for Cancers

As a responsible company, Alfa Chemistry pays special attention to the various diseases that threaten human life and health. We are committed to the development of oligonucleotide therapeutics to treat cancer and have made important progress. Listed below are a few examples of the products we are developing. If you are experiencing bottlenecks in the development of oligonucleotide therapeutics, please contact us to get related technology and assistance.

Our products and services are for research use only and cannot be used for any clinical purposes.

Online Inquiry

* Name

Phone

* Email

* Services & Products of Interest For Cancers

Project Description

* Verification Code

Submit